<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197986</url>
  </required_header>
  <id_info>
    <org_study_id>QBGJ398-302</org_study_id>
    <secondary_id>2019-003248-63</secondary_id>
    <nct_id>NCT04197986</nct_id>
  </id_info>
  <brief_title>Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations</brief_title>
  <official_title>Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QED Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QED Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate
      the efficacy of giving an oral targeted FGFR1-3 inhibitor, infigratinib, as adjuvant
      treatment following surgery in adult subjects with invasive urothelial carcinoma and
      susceptible FGFR3 genetic alterations (mutations, and gene fusions or translocations [ie,
      rearrangements) who have disease that is considered at high risk for recurrence with surgery
      alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper
      tract urothelial cancer post distal ureterectomy and/or nephrectomy. Study treatment is
      randomized between infigratinib or placebo with treatment until invasive local or distal
      disease recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned (1:1) to receive oral infigratinib phosphate or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>As a double-blind study, participants, investigators, study monitor(s) and the clinical study team will be blinded to the treatment administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Centrally determine disease-free survival (DFS)</measure>
    <time_frame>Randomization through 1 year after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare DFS including intraluminal low-risk recurrence</measure>
    <time_frame>Randomization through up to an approximated 5 years (60 months) after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare metastasis-free survival (MFS)</measure>
    <time_frame>Randomization through 1 year after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival (OS)</measure>
    <time_frame>Randomization through 1 year after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare investigator-reviewed DFS</measure>
    <time_frame>Randomization through 1 year after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability</measure>
    <time_frame>30-Day Post-Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Upper Tract Urothelial Carcinomas</condition>
  <condition>Urothelial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Infigratinib 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib</intervention_name>
    <description>Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.</description>
    <arm_group_label>Infigratinib 125 mg</arm_group_label>
    <other_name>IP</other_name>
    <other_name>Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Have histologically or cytologically confirmed, invasive urothelial carcinoma with
             susceptible FGFR3 alterations within 120 days following nephroureterectomy, distal
             ureterectomy, or cystectomy

          2. If the patient received neoadjuvant chemotherapy, pathologic stage at surgical
             resection must be AJCC Stage ≥ ypT2 and/or yN+.

          3. If the patient did not receive neoadjuvant chemotherapy:

               1. Must be ineligible to receive cisplatin-based adjuvant chemotherapy per the
                  Galsky criteria:

                    -  creatinine clearance &lt; 60cc/min or

                    -  ≥ Grade 2 hearing loss or

                    -  ≥ Grade 2 neuropathy)

               2. Pathologic stage must be AJCC Stage ≥pT2 pN0-2 M0 (post-lymphadenectomy or no
                  lymphadenectomy [pNx]) for upper tract disease.

               3. Pathologic stage should be AJCC Stage ≥pT3 or pN+ (bladder cancer).

          4. Have Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

          5. Patients must have no evidence of metastatic disease based on screening CT or MRI.

        Exclusion Criteria:

          1. Presence of positive surgical margins following nephroureterectomy, distal
             ureterectomy, or cystectomy.

          2. Have received Bacillus Calmette-Guerin (BCG) or other intravesical therapy for
             Non-Muscle Invasive Bladder Cancer (NMIBC) within the previous 30 days.

          3. Have previously or currently is receiving treatment with a mitogen-activated protein
             kinase (MEK) or selective FGFR inhibitor.

          4. Have impaired gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral infigratinib (eg, active ulcerative diseases,
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel
             resection)

          5. Have current evidence of corneal or retinal disorder/keratopathy.

          6. Have a history and/or current evidence of extensive tissue calcification.

          7. Have current evidence of endocrine alterations of calcium/phosphate homeostasis (eg,
             parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis),
             unless well controlled.

          8. Are currently receiving or are planning to receive during participation in this study,
             treatment with agents that are known strong inducers or inhibitors of CYP3A4 and
             medications which increase serum phosphorus and/or calcium concentration.

          9. Clinically significant cardiac disease.

         10. Recent (&lt; 3 months prior to first dose of study drug) transient ischemic attack or
             stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corina Andresen, MD</last_name>
    <role>Study Director</role>
    <affiliation>QED Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>QED Therapeutics</last_name>
    <phone>1-877-280-5655</phone>
    <email>Proof302.ct@qedtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimbell</last_name>
      <phone>520-668-5678</phone>
      <email>stacey.kimbell@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Disimone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumanta Pal, M.D.</last_name>
      <phone>626-256-4673</phone>
    </contact>
    <investigator>
      <last_name>Sumanta Pal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialist</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Bellamy</last_name>
      <phone>850-696-4423</phone>
      <email>lbellamy@woodlandsmed.com</email>
    </contact>
    <investigator>
      <last_name>Rami Owera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug Hart</last_name>
      <phone>513-751-2273</phone>
      <email>douglas.hart@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>David Waterhouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates, P.C.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxie Felton</last_name>
      <phone>615-250-9240</phone>
      <email>rcfelton@ua-pc.com</email>
    </contact>
    <investigator>
      <last_name>Gautam Jayram, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-757-2122</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>John Lijo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGFR3 Genetic Alterations</keyword>
  <keyword>upper tract urothelial carcinomas</keyword>
  <keyword>UTUC</keyword>
  <keyword>Invasive Urothelial Carcinoma</keyword>
  <keyword>Fibroblast growth factor receptor inhibitor</keyword>
  <keyword>BGJ398</keyword>
  <keyword>FGFR3</keyword>
  <keyword>urothelial bladder cancer</keyword>
  <keyword>UBC</keyword>
  <keyword>Infigratinib phosphate</keyword>
  <keyword>Infigratinib</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

